동향
동향 내용
Rifampicin pharmacokinetics in children under the Revised National Tuberculosis Control Programme
분류 pharmacokinetics 조회 1390
발행년도 2015 등록일 2015-07-31
출처 Int J Tuberc Lung Dis (바로가기)
OBJECTIVE:
To evaluate serum levels of rifampicin (RMP) in children with tuberculosis (TB) at doses administered according to India's Revised National Tuberculosis Control Programme (RNTCP) 2009 report.
 
METHOD:
Prospective, open label, non-randomised single-dose study in 20 children aged 5-12 years.
 
SETTING:
The out-patient chest clinic of a tertiary care hospital, New Delhi, India.
 
RESULTS:
The median RMP dose administered was 9.56 mg/kg (range 9-12.64). Peak RMP concentration (Cmax) attained was 6.24 μg/ml (range 5.44-7.61) at time to Cmax of 3.5 h (range 3-4). RMP levels were significantly lower at 2, 3 and 4 h in children administered <10 mg/kg than those who received ⩾10 mg/kg (P < 0.05). A positive correlation between the RMP dose administered and Cmax was observed (r(2) = 0.748). RMP Cmax was <8 μg/ml in all patients, a level considered too low for therapeutic efficacy.
 
CONCLUSIONS:
Low serum concentrations of RMP were attained in children under the RNTCP 2009 weight band system. Peak RMP levels appear to be lower and the single dose elimination half-life shorter in children than in adults. To optimise treatment outcomes, revisions in RMP dose in children should take into consideration age-related differences in pharmacokinetics.

목록



[추천 메일 발송]
추천 메일 발송
받는 분 이메일 @
추천인
리스트 이전글과 다음글
이전글이전글 Clinical Pharmacokinetics and Pharmacodynamics of the Endothelin Receptor Antagonist Macitentan.
다음글다음글 포스포트랜스아세틸라제 억제 활성을 가지는 화합물을 포함하는 세균 감염 질환 예방 또는 치료용 약제학적 조성물